Envisagenics

company

About

Envisagenics reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$225K
Industries
Artificial Intelligence,Bioinformatics,Biotechnology,Machine Learning,Therapeutics
Founded date
Apr 22, 2014
Number Of Employee
11 - 50
Operating Status
Active

Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence.

Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.

Their breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.

Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$1.82M
Envisagenics has raised a total of $1.82M in funding over 2 rounds. Their latest funding was raised on May 22, 2018 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 22, 2018 Grant $1.50M 1 National Institutes of Health Detail
Aug 13, 2015 Grant $225K 1 Detail
Jul 29, 2015 Debt Financing $100K 2 Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Envisagenics is funded by 3 investors. National Institutes of Health and the Long Island Emerging technologies Fund (LIETF) are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
the Long Island Emerging technologies Fund (LIETF) Debt Financing
Accelerate Long Island Debt Financing